Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

Summary

This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER signalling in ER positive endometrial cancer without delaying standard surgical management.

Timeline

Start

2026-10-26

Primary completion

2028-10-26

Completion

2028-10-26

Drugs

Indications